Founded in 1944, the American Committee develops awareness of and support for the institute in Israel and advances its mission of science for the benefit of humanity. Weizmann scientists average two new patents approved every week. Enbrel, Humira and Copaxone are derived from intellectual property developed at the Weizmann Institute of Science.